NASDAQ:VTGN

VistaGen Therapeutics News Headlines

$2.80
-0.04 (-1.41 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.78
$2.89
50-Day Range
$1.96
$2.98
52-Week Range
$0.46
$3.18
Volume991,479 shs
Average Volume3.12 million shs
Market Capitalization$401.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86

VistaGen Therapeutics (NASDAQ VTGN) News Headlines Today

SourceHeadline
Bullish Case For VistaGen Therapeutics Is Its Pipeline Not Its Stock PriceBullish Case For VistaGen Therapeutics Is Its Pipeline Not Its Stock Price
marketbeat.com - February 22 at 1:07 PM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Post Quarterly Sales of $310,000.00VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Post Quarterly Sales of $310,000.00
americanbankingnews.com - June 12 at 4:34 AM
Zacks: Analysts Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to Post -$0.05 EPSZacks: Analysts Anticipate VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to Post -$0.05 EPS
americanbankingnews.com - June 10 at 3:16 AM
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety DisorderVistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder
finance.yahoo.com - May 26 at 12:38 PM
VistaGen Therapeutics (NASDAQ:VTGN) Now Covered by Analysts at Robert W. BairdVistaGen Therapeutics (NASDAQ:VTGN) Now Covered by Analysts at Robert W. Baird
americanbankingnews.com - May 25 at 10:08 AM
$310,000.00 in Sales Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter$310,000.00 in Sales Expected for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) This Quarter
americanbankingnews.com - May 24 at 2:50 AM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Announce Earnings of -$0.05 Per ShareVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expected to Announce Earnings of -$0.05 Per Share
americanbankingnews.com - May 22 at 2:18 PM
Why VistaGen Therapeutics Stock Is Trading Higher TodayWhy VistaGen Therapeutics' Stock Is Trading Higher Today
msn.com - May 20 at 5:46 PM
VistaGen Therapeutics to Present at Two Investor Conferences in JuneVistaGen Therapeutics to Present at Two Investor Conferences in June
finance.yahoo.com - May 20 at 12:45 PM
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Rating of "Buy" by BrokeragesVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - May 19 at 6:34 PM
Robert W. Baird Begins Coverage on VistaGen Therapeutics (NASDAQ:VTGN)Robert W. Baird Begins Coverage on VistaGen Therapeutics (NASDAQ:VTGN)
americanbankingnews.com - May 19 at 5:22 PM
What Type Of Shareholders Make Up VistaGen Therapeutics, Inc.s (NASDAQ:VTGN) Share Registry?What Type Of Shareholders Make Up VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Share Registry?
finance.yahoo.com - May 19 at 2:44 PM
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial OfficerVistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
finance.yahoo.com - May 4 at 1:04 PM
Novel Anxiety and Depression Approach by VistaGen TherapeuticsNovel Anxiety and Depression Approach by VistaGen Therapeutics
finance.yahoo.com - April 27 at 2:06 PM
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of DirectorsVistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
finance.yahoo.com - April 27 at 8:21 AM
VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive BenzodiazepinesVistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
finance.yahoo.com - March 22 at 1:11 PM
Why Is It Moving? Analyzing The Upward Movement in VistaGen Therapeuticss Stock TodayWhy Is It Moving? Analyzing The Upward Movement in VistaGen Therapeutics's Stock Today
msn.com - March 11 at 1:54 PM
VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical StudyVistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
finance.yahoo.com - March 11 at 8:42 AM
Will SAD Trial Make VistaGen Investors Happy?Will SAD Trial Make VistaGen Investors Happy?
nasdaq.com - February 19 at 8:19 AM
Why VistaGen Therapeutics Stock Is Soaring TodayWhy VistaGen Therapeutics Stock Is Soaring Today
finance.yahoo.com - February 18 at 2:39 PM
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its BusinessVistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
finance.yahoo.com - February 15 at 5:47 PM
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue EstimatesVistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - February 11 at 11:36 PM
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
finance.yahoo.com - February 11 at 6:26 PM
InvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing RequirementsInvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing Requirements
marketwatch.com - January 7 at 12:38 PM
VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing RequirementsVistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
finance.yahoo.com - January 6 at 10:34 AM
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression DisordersVistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
finance.yahoo.com - December 30 at 12:05 PM
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public OfferingVistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
finance.yahoo.com - December 22 at 7:22 PM
VistaGen Therapeutics Announces Pricing of Underwritten Public OfferingVistaGen Therapeutics Announces Pricing of Underwritten Public Offering
finance.yahoo.com - December 18 at 8:31 AM
VistaGen Therapeutics Announces Proposed Underwritten Public OfferingVistaGen Therapeutics Announces Proposed Underwritten Public Offering
finance.yahoo.com - December 17 at 5:27 PM
VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of DepressionVistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
finance.yahoo.com - December 10 at 8:59 AM
BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational MedicineBioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
benzinga.com - December 1 at 7:51 PM
VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational MedicineVistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medicine
finance.yahoo.com - December 1 at 2:51 PM
VISTAGEN THERAPEUTIC (VSTA) Q3 2020 Earnings Call TranscriptVISTAGEN THERAPEUTIC (VSTA) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 19 at 2:02 PM
Earnings Beat: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsEarnings Beat: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
finance.yahoo.com - November 16 at 12:20 PM
VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepinesVistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines
seekingalpha.com - November 12 at 2:00 PM
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn SinghInvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn Singh
finance.yahoo.com - October 27 at 12:16 PM
Vistagen Therapeutics receives listing extension from NASDAQVistagen Therapeutics receives listing extension from NASDAQ
seekingalpha.com - October 14 at 12:27 PM
Vistagen Therapeutics +4.5% on listing extension from NASDAQVistagen Therapeutics +4.5% on listing extension from NASDAQ
seekingalpha.com - October 14 at 12:27 PM
NetworkNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials PublicationNetworkNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication
marketwatch.com - September 29 at 7:27 PM
BioMedNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company UpdateBioMedNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company Update
marketwatch.com - September 28 at 6:04 PM
BioMedNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 - Probenecid CombinationBioMedNewsBreaks - VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 - Probenecid Combination
marketwatch.com - September 10 at 1:03 PM
VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with ProbenecidVistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
finance.yahoo.com - September 3 at 12:45 PM
VistaGen Therapeutics to Present at the LD Micro 500 Virtual ConferenceVistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference
finance.yahoo.com - August 27 at 10:25 AM
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business ProgressVistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
finance.yahoo.com - August 13 at 8:21 PM
VistaGen Therapeutics Announces Exercise and Closing of Underwriters Over-allotment Option in Underwritten Public OfferingVistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
marketwatch.com - August 10 at 8:55 AM
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public OfferingVistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
finance.yahoo.com - August 10 at 8:55 AM
EverInsight pays $5M upfront license payment to VistaGenEverInsight pays $5M upfront license payment to VistaGen
seekingalpha.com - August 4 at 12:01 PM
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Dynatrace, Carnival Corp, Atossa TherapeuticsBUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Dynatrace, Carnival Corp, Atossa Therapeutics
nasdaq.com - August 3 at 3:54 PM
VistaGen Therapeutics Announces Proposed Public Offering Of Common Stock; Size Not DisclosedVistaGen Therapeutics Announces Proposed Public Offering Of Common Stock; Size Not Disclosed
www.benzinga.com - August 3 at 5:54 AM
VistaGen prices equity offering at $0.80VistaGen prices equity offering at $0.80
seekingalpha.com - August 3 at 5:54 AM
VistaGen readies equity offeringVistaGen readies equity offering
seekingalpha.com - July 31 at 7:38 PM
This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.